Wedbush Reiterates Outperform Rating for TScan Therapeutics (NASDAQ:TCRX)

Wedbush reissued their outperform rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report sent to investors on Monday morning,RTT News reports. The firm currently has a $7.00 price target on the stock.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Wednesday, December 11th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price objective on shares of TScan Therapeutics in a report on Wednesday, December 11th.

TScan Therapeutics Stock Performance

Shares of TCRX stock opened at $3.01 on Monday. The company has a market capitalization of $160.65 million, a price-to-earnings ratio of -2.84 and a beta of 0.79. TScan Therapeutics has a 1-year low of $2.60 and a 1-year high of $9.69. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13. The stock’s fifty day simple moving average is $4.57 and its 200-day simple moving average is $5.64.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.03. The company had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $2.86 million. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. On average, sell-side analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TScan Therapeutics

Large investors have recently bought and sold shares of the business. Barclays PLC raised its holdings in TScan Therapeutics by 341.1% during the third quarter. Barclays PLC now owns 58,067 shares of the company’s stock valued at $289,000 after buying an additional 44,903 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of TScan Therapeutics by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 973,466 shares of the company’s stock valued at $4,849,000 after acquiring an additional 72,967 shares in the last quarter. XTX Topco Ltd acquired a new stake in TScan Therapeutics in the 3rd quarter worth approximately $112,000. Wellington Management Group LLP lifted its holdings in TScan Therapeutics by 38.9% in the 3rd quarter. Wellington Management Group LLP now owns 126,345 shares of the company’s stock worth $629,000 after purchasing an additional 35,404 shares during the last quarter. Finally, State Street Corp boosted its position in TScan Therapeutics by 24.4% during the third quarter. State Street Corp now owns 756,499 shares of the company’s stock worth $3,767,000 after purchasing an additional 148,414 shares during the period. 82.83% of the stock is currently owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.